Actively Recruiting

Phase Not Applicable
Age: 3Years - 11Years
All Genders
ID06442592

Characterization and Support for Neurodevelopmental Disorders Associated With Congenital Heart Defects in Children Aged 3 to 11

Led by Nantes University Hospital · Updated on 2026-04-03

1206

Participants Needed

5

Research Sites

4 weeks

Total Duration

On this page

Sponsors

N

Nantes University Hospital

Lead Sponsor

A

Angers University

Collaborating Sponsor

AI-Summary

What this Trial Is About

Congenital Heart Defects (CHD) are the leading cause of birth defects affecting millions worldwide, including 41,000 newborns annually in Europe. Over half of children born with critical CHD develop Neurodevelopmental Disorders (NDs), which impact cognitive, behavioral, and social development. These disorders often appear early, before cardiovascular complications, and affect various functions such as language, learning, memory, and social interactions. The CATAMARAN - Pediatrics project aims to detect neurodevelopmental delays as early as age 3 and identify factors that increase the risk of NDs in children with CHD. The study involves 201 children aged 3 to 11 who had critical CHD and underwent heart surgery within the first three months of life, along with their two parents. Children will undergo neurodevelopmental assessments by neuropsychologists and multidisciplinary teams to identify any disorders. Blood samples will be collected from the children and parents to analyze genetic factors. Parents will complete questionnaires assessing parental stress. The study is non-randomized and observational in nature. Participants will be evaluated over a period of up to 14 days during which neurodevelopmental functioning, quality of life, and parental stress will be assessed. Researchers will measure the prevalence and nature of neurodevelopmental disorders in different age groups and evaluate the accuracy of the multidisciplinary diagnostic approach. Genetic analyses will identify rare and common variants linked to neurodevelopmental disorders. The study continues until August 2027 and aims to improve understanding and support for children with CHD and associated neurodevelopmental challenges.

CONDITIONS

Brief Title

Characterization and Support for Neurodevelopmental Disorders Associated With Congenital Heart Defects

Who Can Participate

Age: 3Years - 11Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Child aged 3 to 11 years with critical congenital heart defect operated on during the first three months of life
  • Biological parents and child affiliated with or benefiting from social security or similar scheme
  • Both parents and child have good understanding of the French language
  • Free, informed, and written consent of both parents for themselves and the child
  • Free, informed, and written consent of the child aged 6 years and over
  • Biological parents willing to participate
Not Eligible

You will not qualify if you...

  • Known genetic anomaly or malformative syndrome associated with neurodevelopmental abnormalities identified before inclusion
  • Neurodevelopmental assessment not practicable

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Surveillance

Duration - Up to 14 days

Participants undergo assessments including blood sampling, neurodevelopment evaluations, and parental stress questionnaires to characterize neurodevelopmental disorders associated with congenital heart defects.

1 to 2 visits depending on assessment type

Trial Site Locations

Total: 5 locations

1

Chu Brest

Brest, Brittany Region, France, 29200

Actively Recruiting

2

CHU Rennes

Rennes, Brittany Region, France, 35000

Actively Recruiting

3

CHU Nantes

Nantes, Loire-Atlantique, France, 44000

Actively Recruiting

4

CHU Angers

Angers, Maine-et-Loire, France, 49000

Actively Recruiting

5

CHU Tours

Tours, Val de Loire, France, 37000

Actively Recruiting

Loading map...

Research Team

A

Alban Baruteau

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

SCREENING

Number of Arms

2

Similar Trials

CATAMARAN - Neonatal Cohort: Characterization and Support of...

Heart Disease Congenital

Actively Recruiting

8 locations

Creation of a French South-Eastern Database and DNA-bank of ...

Congenital Heart Defects

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here